Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...

Researchers at Baylor College of Medicine have discovered a natural mechanism that clears existing amyloid plaques in the brains of mouse models of Alzheimer’s disease and preserves cognitive function ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Researchers from Harvard’s Department of Human Evolutionary Biology found that educated children perform better on psychological tests measuring executive function abilities, challenging the accuracy ...

If we can fully map the structure of our brains, will we be able to understand how they work? That is the goal of researchers attempting to build a wiring diagram, or connectome, of our neural ...

Investors sold out of the biotech following a quarterly earnings release this morning. The company posted a deeper-than-expected net loss. It's common for clinical-stage biotech companies to post net ...

If you spend any time tinkering with or detailing vehicles just a couple of feet off the ground, a rolling stool is a garage essential. And if you sometimes need to get under a car, a creeper can be ...